Imdelltra (tarlatamab-dlle) demonstrated superior overall survival in small cell lung cancer – Amgen

Amgen announced that the global Phase III  DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. Imdelltra  demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.

DeLLphi-304 is a global Phase III randomized controlled open-label clinical trial (NCT05740566) evaluating the efficacy and safety of  Imdelltra  as a treatment for patients with SCLC who progressed on or after a single line of platinum-based chemotherapy. Patients were randomized to receive either  Imdelltra  or local SOC chemotherapy (topotecan in all countries except Japan; lurbinectedin in the U.S., Canada, Australia, Singapore, Korea; and amrubicin in Japan). The primary outcome measure of the trial is OS.

The safety profile for  Imdelltra  was consistent with its known profile. Detailed data from DeLLphi-304 will be presented at an upcoming medical congress.

“Small cell lung cancer is one of the most aggressive malignancies, with a high unmet need for more effective therapies. The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care,” said Dr. jay Bradner, Executive VP, Research and Development, at Amgen. “We look forward to sharing these results with the scientific community and health authorities as we continue our efforts to bring IMDELLTRA to patients worldwide.”